Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 8/20 | 0.95 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 1.00 |
| ▸ | HRH2 | P25021 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | MIF | P14174 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histamine SCHEMBL17377087 | 1.00 | — | — | |
| Histamine SCHEMBL288432 | 0.98 | — | — | |
| Histamine SCHEMBL15532340 | 0.93 | HRH3 (0.91) | HRH3HRH4HRH2APEX1SMN1; SMN2 | |
| Homohistamine SCHEMBL9799515 | 0.87 | HRH3 (0.96) | HRH3HRH4HRH2APEX1SMN1; SMN2 | |
| Histamine SCHEMBL123245 | 0.86 | HRH3 (0.78) | HRH3HRH4HRH2APEX1SMN1; SMN2 | |
| Histamine SCHEMBL27939119 | 0.85 | HRH3 (0.75) | HRH3HRH4HRH2APEX1SMN1; SMN2 | |
| Homohistamine SCHEMBL2092691 | 0.84 | — | — | |
| SCHEMBL8963903 | 0.83 | HRH3 (0.73) | HRH3HRH4HRH2APEX1SMN1; SMN2 | |
| Imbutamine SCHEMBL28015739 | 0.83 | HRH3 (1.00) | HRH3HRH4HRH2APEX1SMN1; SMN2 | |
| Histamine SCHEMBL3960364 | 0.82 | HRH3 (0.70) | HRH3HRH4HRH2APEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4340838-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | Paz, Alberto (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4320143-A1 | METHODS FOR INHIBITING RAS | The General Hospital Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022245650-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | PAZ ALBERTO (US) | 2022-11-24 | — | — | WO | disclosed |
| US-11464217-B2 | Rodents having genetically modified sodium channels and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022212894-A1 | METHODS FOR INHIBITING RAS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-109790162-B | Covalent inhibitors of PAD4 | 帕德罗科治疗公司 | 2022-06-28 | — | — | CN | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3927153-A1 | RODENTS HAVING GENETICALLY MODIFIED SODIUM CHANNELS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| EP-3490989-B1 | COVALENT INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10703741-B2 | Covalent inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190276432-A1 | COVALENT INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2019-09-12 | — | — | US | disclosed |
| CN-110049773-A | TGF β antibody, method and purposes | 供石公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-108430491-A | Peptide | HOX治疗有限公司 | 2018-08-21 | — | — | CN | disclosed |
| CN-105492438-B | Sulfomimine substituted 5-fluoro-N- (pyridin-2-yl) pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors | 拜耳医药股份有限公司 | 2018-08-07 | — | — | CN | disclosed |
| CN-105288647-B | The preparation method of functionalization albumin and its nanometer formulation | 中国药科大学 | 2018-05-25 | — | — | CN | disclosed |
| CN-107207475-A | Fluorination benzofuranyl pyrimidine derivatives containing sulfone group | 拜耳医药股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| US-9527852-B2 | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation | NEUROPORE THERAPIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9487524-B2 | — | — | 2016-11-08 | — | — | US | disclosed |
| US-20150166543-A1 | PHENYL-UREA AND PHENYL-CARBAMATE DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171541-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | HRH1 3814/4885HRH3 1863/4885HRH4 3441/4885 |
| US-20150166543-A1 | PHENYL-UREA AND PHENYL-CARBAMATE DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION | PARK7, PRNP, MAPT | HRH1 3959/4885HRH3 3335/4885HRH4 4031/4885 |
| US-10703741-B2 | Covalent inhibitors of PAD4 | PADI4, PADI1, PADI6 | HRH1 3417/4885HRH3 2515/4885HRH4 2514/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | HRH1 3411/4885HRH3 1189/4885HRH4 2645/4885 |
| US-20190276432-A1 | COVALENT INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | HRH1 3417/4885HRH3 2515/4885HRH4 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.